We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
24
8 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
8
33.3%
Completed
5
20.8%
Recruiting
6
25.0%
Terminated
3
12.5%
Unknown
2
8.3%
No approval data available
- Imugene has activated its first Australian site for the Phase II Neo-POLEM trial, expanding recruitment for its PD1-Vaxx immunotherapy in both Australia and the United Kingdom. - The trial targets patients with mismatch repair-deficient or microsatellite instability-high colorectal cancer, a genetic subtype representing about 15% of colorectal cancer cases. - PD1-Vaxx is a neoadjuvant B-cell vaccine designed to trigger immune responses against PD-1, administered before surgery to evaluate major pathological response and tumor shrinkage. - Colorectal cancer affects more than 1.2 million new patients annually worldwide, with approximately 80% presenting with localized disease yet maintaining a 50% global mortality rate.
